Novo's CagriSema helped women lose 25% of weight on average, analysis shows

A Reddit community post, r/GLP1ResearchTalk, summarized a Reuters report that Novo Nordisk presented at The Menopause Society annual meeting data showing CagriSema achieved roughly 25% average weight loss in women in the REDEFINE 1 trial (26.7% premenopausal, 24.8% perimenopausal, 23.1% postmenopausal; 22.7% overall, below the 25% target). Commenters noted this was a post hoc subgroup analysis and that women generally respond better to GLP-1 drugs for weight loss.